

22<sup>ND</sup> ANNUAL

# LYNN SAGE BREAST CANCER SYMPOSIUM

SEPTEMBER 10 - 12, 2020



**VIRTUAL  
FOR 2020**

**SYMPOSIUM CHAIR**

William Gradishar, MD

**SYMPOSIUM CO-CHAIR**

Monica Morrow, MD

**SCIENTIFIC PLANNING COMMITTEE**

Nora Hansen, MD

Kalliopi Siziopikou, MD, PhD

Jonathan Strauss, MD, MBA



**VISIT OUR WEBSITE**  
[lynnsagebreastcancer.org](http://lynnsagebreastcancer.org)



Referred to as the most valuable breast cancer meeting worldwide for the practicing clinician, the Lynn Sage Breast Cancer Symposium provides 3 days of formal presentations and interactive case discussions. For over 20 years, this multidisciplinary CME program has been bringing together leading national and international medical, surgical, and radiation oncologists to present, debate, and evaluate cutting-edge technology and approaches in the management of breast cancer.

Progress across all aspects of patient care, including prevention, screening, detection and survivorship, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy and novel biologic therapies are leading to new strategies and therapeutic options. This symposium focuses on the close cooperation required for effective multidisciplinary management of patients with breast cancer.

## **Educational Objectives**

At the conclusion of this activity, participants will be able to:

1. Discuss optimal evaluation and management of women at increased risk for breast cancer.
2. Analyze application of neoadjuvant endocrine therapy in operable cancer.
3. Describe the role of new technology in radiology and radiotherapy.
4. Identify new approaches to systemic therapy and how they may influence surgical management.

## **Target Audience**

The target audience for this activity includes medical oncologists, surgical oncologists, radiation oncologists, internal medicine and other health professionals who interact with or treat breast cancer patients and survivors.



# SEPTEMBER 10 THURSDAY

---

## Session 1: Supportive Care

Moderator: Nora Hansen, MD

---

9:00 am

### **Symposium Welcome**

William Gradishar, MD, Symposium Chair

---

9:05 am

### **Managing the Side Effects of Endocrine Therapy**

Dawn Hershman, MD

---

9:35 am

### **New Approaches to Pain Management in Breast Surgery**

Tracy-Ann Moo, MD

---

10:05 am

### **Current Considerations for Lymphedema Diagnosis and Treatment**

Sarah McLaughlin, MD

---

10:35 am **Break**

---

10:50 am

### **Delivering Survivorship Care**

Sheetal Kircher, MD

---

11:20 am **Q&A**

---

11:35 am **Lunch Break & Exhibits**

---

11:35 am

Optional Non-CME: Sponsored by Lilly

### **A Treatment Option for Patients With HR+, HER2- Advanced or Metastatic Breast Cancer**

12:05 pm **Break**

---

## Session 2: Breast Pathology for the Non-Pathologist

Moderator: Kalliopi Siziopikou, MD, PhD

---

12:10 pm

### **Evaluation of Pathologic Response After Neoadjuvant Chemotherapy: A Continuing Challenge**

Kalliopi Siziopikou, MD, PhD

---

12:40 pm

### **PDL-1 Assessment: What's Important, What's Not?**

David Rimm, MD, PhD

---

1:10 pm

### **WHO Classification of Breast Tumors: The 2019 Update**

Luis Blanco, Jr., MD

---

1:40 pm

### **Genomic Tools That Predict Response in Breast Cancer**

Virginia Kaklamani, MD, DSc

---

2:10 pm **Q&A**

---

2:25 pm **Adjourn**



# SEPTEMBER 11 FRIDAY

## Session 4: Breast Imaging and Risk Management

Moderator: Seema Khan, MD

9:00 am

### Update on Contrast Mammography

Maxine Jochelson, MD

9:30 am

### Machine Learning as a Tool to Improve Breast Imaging

Connie Lehman, MD, PhD

10:00 am

### Assessing Genetic Risk 2020

Banu Arun, MD

10:30 am **Break**

10:45 am

### Controversies in Surgical Management of BRCA Carriers

Mary Gemignani, MD, MPH

11:15 am

### Genetic Testing in Practice: Perceptions of Patients and Physicians

Steven Katz, MD

11:45 am **Q&A**

12:00 pm **Lunch Break & Exhibits**

12:05 pm

Optional Non-CME: Sponsored by Seattle Genetics

### A New Treatment in HER2+ Metastatic Breast Cancer

## Session 5: New Approaches to Old Problems

Moderator: Massimo Cristofanilli, MD

12:40 pm

### Male Breast Cancer: Is it Really Worse?

Anthony Elias, MD

1:10 pm

### Detection and Treatment of Minimal Residual Disease: The Way Forward?

Lajos Pusztai, MD, DPhil

1:40 pm

### Patterns of Tumor Response Following NAC: Implications for Local Therapy

Stuart Schnitt, MD

2:10 pm **Break**

2:25 pm

### Proton Radiotherapy for Breast Cancer: Advance or Fad?

Jonathan Strauss, MD, MBA

2:55 pm

### Delay in Breast Cancer Treatment: Is it Harmful?

Richard Bleicher, MD

3:25 pm **Q&A**

3:40 pm **Adjourn**





# SEPTEMBER 12 SATURDAY

8:15 am

Optional Non-CME: Sponsored by DSI

**Updates on the Treatment of Patients With Unresectable or Metastatic HER2+ Breast Cancer Who Previously Received Anti-Her2 Therapies**

**Session 6: Current Approach to Advanced Disease**

Moderator: William Gradishar, MD

9:00 am

**Novel Endocrine Agents**

William Gradishar, MD

9:30 am

**Update on Brain Metastases**

Carey Anders, MD

10:00 am

**Stereotactic Body Radiation Therapy for Oligometastases**

Steve Chmura, MD, PhD

10:30 am **Break**

10:45 am

**Metastatic Triple Negative Breast Cancer**

Kari Wisinski, MD

11:15 am

**Surgery of the Primary Tumor in Stage 4 Breast Cancer**

Seema Khan, MD

11:45 am **Q&A**

12:00 pm **Lunch Break & Exhibits**

12:05 pm

Optional Non-CME: Sponsored by Genentech

**HER2 Positive Early Breast Cancer: Determining Adjuvant Treatment Following Neoadjuvant Therapy**

12:35 pm **Break**

**Session 7: Emerging Issues in Breast Cancer Management**

Moderator: Jonathan Strauss, MD, MBA

12:40 pm

**Financial Toxicity of Breast Cancer Treatment**

Reshma Jagsi, MD, DPhil

1:10 pm

**Will Surgery Be a Part of Breast Cancer Therapy in the Future?**

Monica Morrow, MD

1:40 pm

**Implant Associated Lymphoma**

Jonas Nelson, MD

2:10 pm **Q&A**

2:25 pm **Break**

**Session 8: Issues in Neoadjuvant Therapy**

Moderator: Monica Morrow, MD

2:40 pm

**Decision Making for Neoadjuvant Therapy in ER+ Patients**

Otto Metzger, MD

3:10 pm

**Surgical Issues After Neoadjuvant Endocrine Therapy**

Tari King, MD

3:40 pm

**Radiotherapy Decision Making After Pathological Complete Response**

Julia White, MD

4:10 pm **Q&A**

4:25 pm **Adjourn**



## Registration

Advance registration is encouraged to ensure prompt access to the Virtual Symposium. The registration fee includes conference tuition, CME credits, MOC points, access to digital materials and networking opportunities. Register online at [lynnstagebreastcancer.org](https://lynnstagebreastcancer.org).

Type	Price
Physician	\$375
LMIC* Physician	\$100
Nurse/Nurse Practitioner/Fellow/Other Allied Health	\$75
LMIC* Nurse/Nurse Practitioner/Fellow/Other Allied Health	\$25
Industry	\$595

\*Registrants who reside in LMIC countries as defined by the World Bank Group.

## Refund/Cancellation Policy

Registration fees, less a \$50 administrative handling fee, are refundable if written request is received on or before August 15, 2020. Please include your registration ID number when requesting a refund. **No refunds will be granted after August 15, 2020.** However, you may transfer your registration to a colleague. For further information, please call 312-503-7809 or email [cancer@northwestern.edu](mailto:cancer@northwestern.edu).

# CONFIRMED FACULTY

---

**Carey Anders, MD**

Duke University  
School of Medicine

---

**Banu Arun, MD**

University of Texas  
MD Anderson Cancer Center

---

**Luis Blanco, Jr., MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Richard Bleicher, MD**

Fox Chase Cancer Center

---

**Steven Chmura, MD, PhD**

University of Chicago Medicine

---

**Massimo Cristofanilli, MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Anthony Elias, MD**

University of Colorado  
School of Medicine

---

**Mary Gemignani, MD, MPH**

Memorial Sloan Kettering  
Cancer Center

---

**William Gradishar, MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Nora Hansen, MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

---

**Dawn Hershman, MD**

Herbert Irving Comprehensive  
Cancer Center  
Columbia University Mailman  
School of Public Health

---

**Reshma Jagsi, MD, DPhil**

University of Michigan

---

**Maxine Jochelson, MD**

Memorial Sloan Kettering  
Cancer Center

---

**Virginia Kaklamani, MD, DSc**

UT Health San Antonio  
MD Anderson Cancer Center

---

**Steven Katz, MD**

University of Michigan

---

**Seema Khan, MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Tari King, MD**

Harvard Medical School  
Dana-Farber Cancer Institute

---

**Sheetal Kircher, MD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Connie Lehman, MD, PhD**

Massachusetts General  
Hospital

---

**Sarah McLaughlin, MD**

Mayo Clinic

---

**Otto Metzger, MD**

Harvard Medical School  
Dana-Farber Cancer Institute

---

---

**Tracy-Ann Moo, MD**

Memorial Sloan Kettering  
Cancer Center

---

**Monica Morrow, MD**

Memorial Sloan Kettering  
Cancer Center

---

**Jonas Nelson, MD**

Memorial Sloan Kettering  
Cancer Center

---

**Lajos Pusztai, MD, DPhil**

Yale Cancer Center  
Yale School of Medicine

---

**David Rimm, MD, PhD**

Yale Cancer Center  
Yale School of Medicine

---

**Stuart Schnitt, MD**

Harvard Medical School  
Dana-Farber Cancer Institute

---

**Kalliopi Siziopikou, MD, PhD**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Jonathan Strauss, MD, MBA**

Robert H. Lurie  
Comprehensive Cancer Center  
of Northwestern University

---

**Julia White, MD**

The Ohio State University  
Comprehensive Cancer Center

---

**Kari Wisinski, MD**

University of Wisconsin  
School of Medicine and  
Public Health

---

## Faculty Disclosure

Northwestern University FSM requires course directors, speakers, instructors, planners and other individuals who are in a position to control the content of this activity to disclose any relevant financial relationships. All identified potential conflicts of interest, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations are thoroughly vetted by Northwestern University FSM for fair balance. The faculty disclosures will be indicated in the course syllabus.



ROBERT H. LURIE  
COMPREHENSIVE CANCER CENTER  
OF NORTHWESTERN UNIVERSITY

625 N. Michigan Ave, Suite 1000  
Chicago, Illinois 60611

---

### Accreditation Statement

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

---

### Credit Designation Statement

The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 16.25 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

### Other Credits

The American Academy of Nurse Practitioners and the American Nurses Credentialing Center accept *AMA PRA Category 1 Credit(s)*<sup>™</sup> from organizations accredited by the ACCME.

---

### Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For additional information or to register,  
visit [lynnsagebreastcancer.org](https://lynnsagebreastcancer.org) or call 312-503-7809.